600725-25-5Relevant academic research and scientific papers
1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Page/Page column 154-155, (2020/12/11)
The present invention relates to 1,3,4-oxadiazole derivative compounds having a histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, a use thereof in preparation of a medicament, a pharmaceutical composition comprising the same, a therapeutic method using the composition, and a method for preparing the same, and the 1,3,4-oxadiazole derivative compounds are represented by a following chemical formula (I).
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening
Wellaway, Christopher R.,Amans, Dominique,Bamborough, Paul,Barnett, Heather,Bit, Rino A.,Brown, Jack A.,Carlson, Neil R.,Chung, Chun-Wa,Cooper, Anthony W. J.,Craggs, Peter D.,Davis, Robert P.,Dean, Tony W.,Evans, John P.,Gordon, Laurie,Harada, Isobel L.,Hirst, David J.,Humphreys, Philip G.,Jones, Katherine L.,Lewis, Antonia J.,Lindon, Matthew J.,Lugo, Dave,Mahmood, Mahnoor,McCleary, Scott,Medeiros, Patricia,Mitchell, Darren J.,O'Sullivan, Michael,Le Gall, Armelle,Patel, Vipulkumar K.,Patten, Chris,Poole, Darren L.,Shah, Rishi R.,Smith, Jane E.,Stafford, Kayleigh A. J.,Thomas, Pamela J.,Vimal, Mythily,Wall, Ian D.,Watson, Robert J.,Wellaway, Natalie,Yao, Gang,Prinjha, Rab K.
, p. 714 - 746 (2020/02/04)
The bromodomain and extraterminal (BET) family of bromodomain-containing proteins are important regulators of the epigenome through their ability to recognize N-acetyl lysine (KAc) post-translational modifications on histone tails. These interactions have been implicated in various disease states and, consequently, disruption of BET-KAc binding has emerged as an attractive therapeutic strategy with a number of small molecule inhibitors now under investigation in the clinic. However, until the utility of these advanced candidates is fully assessed by these trials, there remains scope for the discovery of inhibitors from new chemotypes with alternative physicochemical, pharmacokinetic, and pharmacodynamic profiles. Herein, we describe the discovery of a candidate-quality dimethylpyridone benzimidazole compound which originated from the hybridization of a dimethylphenol benzimidazole series, identified using encoded library technology, with an N-methyl pyridone series identified through fragment screening. Optimization via structure- and property-based design led to I-BET469, which possesses favorable oral pharmacokinetic properties, displays activity in vivo, and is projected to have a low human efficacious dose.
Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
-
Page 22, (2008/06/13)
The present invention relates to substituted piperidines of general formula wherein R, R2 to R5, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.
